Episode
ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck
- Podcast
- BioSpace
- Published
- Jun 3, 2026
- Duration seconds
- 1624
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/asco-wins-from-revmed-akeso-summit-more-plus-more-lilly-and-more-china-ada-on-deck/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/biospace-6696251/asco-wins-from-revmed-akeso-summit-more-plus-more-lilly-and-more-china-ada-on-deck.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past weekend, packed plenary sessions from Revolution Medicines and Summit Therapeutics’ Chinese partner Akeso stole the show . For RevMed, analysts anticipate a potential approval in pancreatic cancer as early as this year, while Summit still has a tough road ahead showing that the survival benefit seen in Akeso’s clinical trial in China will hold up in a global population . Immuneering , BMS/BioNTech , Merck , Pfizer and many more also scored oncology wins at the annual meeting, as did Moderna, with “encouraging” 5-year survival for its mRNA-based personalized melanoma vaccine. Outside of ASCO, the past week saw Pfizer strike an unusual pact with China’s Innovent Biologics as it seeks to bolster its oncology pipeline . Reminiscent of another recent deal from BMS and Hengrui Pharma, it could signal a more collaborative approach to working with Chinese companies. We’ll also cover the latest deals from Eli Lilly, which continues to rack up partners with its GLP-1 windfall. Finally, learn about how BrainStorm is planning another FDA bid for its experimental ALS therapy NurOwn with former regulator Peter Pitts now on the board, and check out a preview of the 2026 American Diabetes Association, or ADA, which kicks off this weekend in New Orleans.